Reviewing Aravive Inc. (ARAV)’s and Its Rivals results

As Biotechnology company, Aravive Inc. (NASDAQ:ARAV) is competing with its peers based on the risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Insider & Institutional Ownership

30% of Aravive Inc.’s shares are owned by institutional investors. Comparatively, 53.20% of all Biotechnology’s companies shares are owned by institutional investors. 0.8% of Aravive Inc. shares are owned by company insiders. Comparatively, 8.45% of all Biotechnology companies shares are owned by company insiders.


On first table we have Aravive Inc. and its peers’ return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Aravive Inc. 101,212,938.01% -116.40% -97.40%
Industry Average 812.10% 105.95% 28.39%

Valuation and Earnings

In next table we are comparing Aravive Inc. and its peers’ gross revenue, valuation and net income.

Net Income Gross Revenue Price/Earnings Ratio
Aravive Inc. 7.51M 7 0.00
Industry Average 33.76M 4.16M 35.97

Analyst Recommendations

Table 3 shows breakdown of recent ratings for Aravive Inc. and its peers.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aravive Inc. 0 0 1 3.00
Industry Average 1.10 1.78 2.38 2.81

Aravive Inc. currently has an average price target of $18, suggesting a potential upside of 57.89%. The competitors have a potential upside of 168.19%. The analysts’ view based on the results shown earlier is that Aravive Inc. is looking more favorable than its peers.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Aravive Inc. and its competitors.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aravive Inc. 16.13% 9.72% 3.8% 72.82% -38.5% 86.08%
Industry Average 5.82% 9.20% 28.08% 41.63% 73.35% 54.83%

For the past year Aravive Inc.’s stock price has bigger growth than the average for its peers.


The Current Ratio and a Quick Ratio of Aravive Inc. are 7.8 and 7.8. Competitively, Aravive Inc.’s competitors have 7.07 and 6.86 for Current and Quick Ratio. Aravive Inc. has better ability to pay short and long-term obligations than Aravive Inc.’s peers.

Volatility and Risk

A beta of 2.19 shows that Aravive Inc. is 119.00% more volatile than S&P 500. Competitively, Aravive Inc.’s competitors are 76.75% more volatile than S&P 500, because of the 1.77 beta.


Aravive Inc. does not pay a dividend.


Aravive Inc. beats on 3 of the 4 factors Aravive Inc.’s peers.

Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. It is developing AVB-S6-500, a GAS6 binding protein and AXL decoy receptor, for the treatment of ovarian cancer, as well as for renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is based in Houston, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.